NIH plans to shrink the share of grant applications it will award for the remainder of the fiscal year, in some cases by more ...

The landscape of cancer therapeutics is rapidly evolving with the emergence of sophisticated biologics designed to deliver highly targeted and potent ...

Organ transplantation remains the most effective treatment for end-stage diseases. However, persistent challenges such as organ shortage, immune rejection, ...

Detailed price information for Champions Oncolog (CSBR-Q) from The Globe and Mail including charting and trades.

BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, today announced its Chief Scientific Officer, Alan Korman, Ph.D. is the 2025 recipient of one of the ...

The end of the undruggable: Targeted protein degradation therapies open new frontiers in cancer care The 3D-structure of PROTAC® (PROteolysis TArgeting Chimera, a type of TPD) ...